{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:41:29Z","timestamp":1765888889834,"version":"3.40.5"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007861","name":"University of Gondar","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007861","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Though many trials had examined the effectiveness of taking insulin with or without oral agents, there are limited real-world data, particularly among patients with type 2 diabetes mellitus (T2DM) in the resource limited settings. This study aimed to examine level of glycemic control among patients with T2DM after initiation of insulin and factors associated with poor glycemic control.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>An analysis of retrospective medical records of patients with T2DM who initiated insulin due to uncontrolled hyperglycemia by oral agents was conducted from 2015\u20132020 in the University of Gondar Comprehensive Specialized Hospital. Difference in median fasting plasma glucose (FPG) before and after insulin initiations was examined by a Wilcoxon signed-rank test. Kruskal Wallis test was performed to explore difference in the median level of FPG among treatment groups. A logistic regression model was also used to identify associated factors of poor glycemic control after insulin initiation. Statistical significance was declared at p &lt; 0.05.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Of 424 enrolled patients with T2DM, 54.7% were males and the mean age was 59.3\u00b19.3 years. A Wilcoxon signed-rank test showed that there was significant deference in FPG before and after insulin initiation (P &lt; 0.001). A declining trend of blood glucose was observed during the 1-year follow-up period of post-initiation. However, majority of the participants did not achieve target glucose levels. Participants who had higher FPG and systolic blood pressure (SBP) before insulin initiation were found more likely to have poor glycemic control after insulin initiation. Similarly, patients who received atorvastatin compared with simvastatin were found to have poor glycemic control in the post-period of initiation (P = 0.04). Premixed insulin was associated with a lower likelihood of poor glycemic control than neutral protamine Hagedorn (NPH) insulin (P &lt; 0.001).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Following insulin initiation, a significant change in glycemic level and declining trend of FPG was observed during a 1-year follow-up period. However, the majority of patients still had a poorly controlled glycemic level. Appropriate management focusing on predictors of glycemic control would be of a great benefit to achieve glycemic control.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0268639","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T17:35:01Z","timestamp":1653586501000},"page":"e0268639","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Glycemic control in newly insulin-initiated patients with type 2 diabetes mellitus: A retrospective follow-up study at a university hospital in Ethiopia"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5982-853X","authenticated-orcid":true,"given":"Ashenafi Kibret","family":"Sendekie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achamyeleh Birhanu","family":"Teshale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonas Getaye","family":"Tefera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"volume-title":"World health statistics 2018: monitoring health for the SDGs, sustainable development goals","year":"2018","author":"World Health O","key":"pone.0268639.ref001"},{"issue":"10","key":"pone.0268639.ref002","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jama.2017.0241","article-title":"Management of Type 2 Diabetes in 2017: Getting to Goal","volume":"317","author":"JE Reusch","year":"2017","journal-title":"Jama"},{"key":"pone.0268639.ref003","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/ijcp.12154","article-title":"Choice of early treatment regimen and impact on \u03b2-cell preservation in type 2 diabetes","volume":"67","author":"S. Mudaliar","year":"2013","journal-title":"International journal of clinical practice"},{"issue":"9922","key":"pone.0268639.ref004","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","article-title":"Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future","volume":"383","author":"SE Kahn","year":"2014","journal-title":"Lancet (London, England)"},{"key":"pone.0268639.ref005","first-page":"10","article-title":"Five-Year Predictors of Insulin Initiation in People with Type 2 Diabetes under Real-Life Conditions","volume":"2018","author":"SF Gentile Sandro","year":"2018","journal-title":"Journal of Diabetes Research"},{"issue":"11","key":"pone.0268639.ref006","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S0026-0495(99)90141-5","article-title":"Cochlear dysfunction in type 2 diabetes: a complication independent of neuropathy and acute hyperglycemia","volume":"48","author":"FC Sasso","year":"1999","journal-title":"Metabolism: clinical and experimental"},{"issue":"2","key":"pone.0268639.ref007","first-page":"e3494","volume":"38","author":"G Defeudis","year":"2022","journal-title":"Erectile dysfunction and diabetes: A melting pot of circumstances and treatments"},{"issue":"4","key":"pone.0268639.ref008","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2337\/dc18-1965","article-title":"Frailty and Risk of Fractures in Patients With Type 2 Diabetes","volume":"42","author":"G Li","year":"2019","journal-title":"Diabetes care"},{"key":"pone.0268639.ref009","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"H Sun","year":"2022","journal-title":"Diabetes research and clinical practice"},{"issue":"1","key":"pone.0268639.ref010","doi-asserted-by":"crossref","first-page":"21733","DOI":"10.1038\/s41598-021-01256-9","article-title":"Prevalence and risk factors of type-2 diabetes mellitus in Ethiopia: systematic review and meta-analysis","volume":"11","author":"MA Zeru","year":"2021","journal-title":"Scientific Reports"},{"issue":"Suppl 1","key":"pone.0268639.ref011","first-page":"S55","article-title":"6. Glycemic Targets: Standards of Medical Care in Diabetes-2018","volume":"41","year":"2018","journal-title":"Diabetes care"},{"issue":"1","key":"pone.0268639.ref012","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"SE Inzucchi","year":"2015","journal-title":"Diabetes care"},{"issue":"4","key":"pone.0268639.ref013","first-page":"383","article-title":"Continuous Glucose Monitoring Sensors for Diabetes Management","volume":"43","author":"G Cappon","year":"2019","journal-title":"A Review of Technologies and Applications"},{"issue":"5","key":"pone.0268639.ref014","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1210\/jc.2011-2202","article-title":"Update on insulin therapy for type 2 diabetes","volume":"97","author":"T Donner","year":"2012","journal-title":"The Journal of clinical endocrinology and metabolism"},{"issue":"9","key":"pone.0268639.ref015","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/j.1464-5491.2011.03329.x","article-title":"Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life. A prospective cohort study in primary care","volume":"28","author":"TR Hajos","year":"2011","journal-title":"Diabetic medicine: a journal of the British Diabetic Association"},{"key":"pone.0268639.ref016","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1472-6823-9-19","article-title":"The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study","volume":"9","author":"G Goodall","year":"2009","journal-title":"BMC endocrine disorders"},{"issue":"Supply 2","key":"pone.0268639.ref017","first-page":"S220","article-title":"Lucidi, Paola, MD, PHD; Porcellati, Francesca, MD, PHD; Fanelli, Carmine G, MD, PHD. Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2","volume":"34","author":"MD Bolli GB","year":"2011","journal-title":"Diabetes. Diabetes care"},{"issue":"4","key":"pone.0268639.ref018","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/dom.12626","article-title":"Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin","volume":"18","author":"K Khunti","year":"2016","journal-title":"Diabetes, obesity & metabolism"},{"issue":"1","key":"pone.0268639.ref019","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1745-7599.2012.00721.x","article-title":"Insulin initiation in type 2 diabetes: what are the treatment regimen options and how can we best help patients feel empowered?","volume":"24","author":"GR Spollett","year":"2012","journal-title":"Journal of the American Academy of Nurse Practitioners."},{"issue":"2","key":"pone.0268639.ref020","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2337\/diacare.25.2.330","article-title":"Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)","volume":"25","author":"A. B Wright","year":"2002","journal-title":"Diabetes care"},{"issue":"4","key":"pone.0268639.ref021","first-page":"1068","article-title":"Comment on: Warfarin adherence and anticoagulation control in atrial fibrillation patients-a systematic review","volume":"26","author":"A Caturano","year":"2022","journal-title":"European review for medical and pharmacological sciences"},{"issue":"1","key":"pone.0268639.ref022","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s42000-018-0005-9","article-title":"Conversation Maps\u2122, an effective tool for the management of males and females with type 2 diabetes and mildly impaired glycemic control","volume":"17","author":"G Defeudis","year":"2018","journal-title":"Hormones (Athens, Greece)"},{"issue":"8","key":"pone.0268639.ref023","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/01.hjh.0000239303.93872.31","article-title":"Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings","volume":"24","author":"R Minutolo","year":"2006","journal-title":"Journal of hypertension"},{"issue":"13","key":"pone.0268639.ref024","first-page":"1312","article-title":"Metformin for Type 2","volume":"322","author":"A Caturano","year":"2019","journal-title":"Diabetes. Jama"},{"issue":"1","key":"pone.0268639.ref025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/157339911794273892","article-title":"Long-acting insulin analogs: a review of \"real-world\" effectiveness in patients with type 2 diabetes","volume":"7","author":"R. F E-AKM Pollock","year":"2011","journal-title":"Current diabetes reviews"},{"issue":"7","key":"pone.0268639.ref026","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1111\/j.1464-5491.2012.03586.x","article-title":"Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin","volume":"29","author":"B.T SHT Blak","year":"2012","journal-title":"Diabetic medicine: a journal of the British Diabetic Association"},{"issue":"6","key":"pone.0268639.ref027","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach","volume":"35","author":"E. BRMB Inzucchi Silvio","year":"2012","journal-title":"Diabetes care"},{"issue":"6","key":"pone.0268639.ref028","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.2337\/dc13-0512","article-title":"Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors\u2019 Expert Forum","volume":"36","author":"RMC Raz Itamar","year":"2013","journal-title":"Diabetes care"},{"issue":"4","key":"pone.0268639.ref029","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1210\/jc.2009-1966","article-title":"Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know","volume":"95","author":"RJ Smith","year":"2010","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"pone.0268639.ref030","first-page":"e1771","article-title":"Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses","volume":"344","author":"B Hemmingsen","year":"2012","journal-title":"BMJ (Clinical research ed)."},{"issue":"8","key":"pone.0268639.ref031","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jdiacomp.2015.05.022","article-title":"Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy","volume":"29","author":"P Hollander","year":"2015","journal-title":"Journal of diabetes and its complications"},{"issue":"2","key":"pone.0268639.ref032","doi-asserted-by":"crossref","first-page":"e008376","DOI":"10.1136\/bmjopen-2015-008376","article-title":"Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial","volume":"6","author":"L Lundby-Christensen","year":"2016","journal-title":"BMJ open."},{"key":"pone.0268639.ref033","doi-asserted-by":"crossref","DOI":"10.15761\/IOD.1000209","volume-title":"Assessment of factors associated with poor glycemic control among patients with Type II Diabetes mellitus","author":"A Kakade","year":"2018"},{"issue":"2","key":"pone.0268639.ref034","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.2337\/dc09-S319","article-title":"Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents: basal or prandial insulin? The APOLLO trial and beyond","volume":"32","author":"RG Bretzel","year":"2009","journal-title":"Diabetes care"},{"issue":"11","key":"pone.0268639.ref035","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"MC Riddle","year":"2003","journal-title":"Diabetes care"},{"issue":"3","key":"pone.0268639.ref036","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s13300-018-0413-5","article-title":"Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA","volume":"9","author":"L Blonde","year":"2018","journal-title":"Diabetes Ther"},{"issue":"1","key":"pone.0268639.ref037","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/1753-0407.12373","article-title":"Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets","volume":"9","author":"M Mata-Cases","year":"2017","journal-title":"Journal of diabetes"},{"issue":"3","key":"pone.0268639.ref038","first-page":"345","article-title":"Glycemic Control among Patients with Type 2 Diabetes Mellitus in Countries of Arabic Gulf","volume":"9","author":"AA Al-Rasheedi","year":"2015","journal-title":"Int J Health Sci (Qassim)"},{"key":"pone.0268639.ref039","first-page":"81","article-title":"Chirwa Ts. The achievement of glycaemic, blood pressure and LDL cholesterol targets in patients with type 2 diabetes attending a South African tertiary hospital outpatient clinic.","volume":"20","author":"Y Pinchevsky","year":"2015","journal-title":"JEMDSA"},{"issue":"2","key":"pone.0268639.ref040","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diacare.28.2.254","article-title":"Comparison of Basal Insulin Added to Oral Agents Versus Twice-Daily Premixed Insulin as Initial Insulin Therapy for Type 2 Diabetes","volume":"28","author":"HU Janka","year":"2005","journal-title":"Diabetes care"},{"issue":"9","key":"pone.0268639.ref041","first-page":"Cd006992","article-title":"Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control","volume":"9","author":"RC Vos","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"pone.0268639.ref042","doi-asserted-by":"crossref","first-page":"e65600","DOI":"10.5812\/ijem.65600","article-title":"Insulin Monotherapy Versus Insulin Combined with Other Glucose-Lowering Agents in Type 2 Diabetes: A Narrative Review","volume":"16","author":"H Abdi","year":"2018","journal-title":"International journal of endocrinology and metabolism"},{"issue":"2","key":"pone.0268639.ref043","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s13300-019-0584-8","article-title":"Addition of Basal Insulin to Oral Antidiabetic Agents in Patients with Inadequately Controlled Type 2 Diabetes Leads to Improved HbA1c Levels: Metabolic Control, Frequency of Hypoglycemia, and Insulin Titration Analysis as Results of a Prospective Observational Study (BALI Study)","volume":"10","author":"J Bro\u017e","year":"2019","journal-title":"Diabetes Ther."},{"issue":"5","key":"pone.0268639.ref044","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s13300-018-0485-2","article-title":"Current Level of Glycemic Control and Clinical Inertia in Subjects Using Insulin for the Treatment of Type 1 and Type 2 Diabetes in the Czech Republic and the Slovak Republic: Results of a Multinational, Multicenter, Observational Survey (DIAINFORM)","volume":"9","author":"J Bro\u017e","year":"2018","journal-title":"Diabetes Ther."},{"key":"pone.0268639.ref045","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1474651410370659","article-title":"Insulin usage in type 2 diabetes mellitus patients in UK clinical practice: a retrospective cohort-based analysis using the THIN database.","volume":"10","author":"M Evans","year":"2010","journal-title":"The British Journal of Diabetes & Vascular Disease"},{"key":"pone.0268639.ref046","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.diabres.2019.01.017","article-title":"Patterns and trends in insulin initiation and intensification among patients with Type 2 diabetes mellitus in the Middle East and North Africa region","volume":"149","author":"A Jabbar","year":"2019","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"7","key":"pone.0268639.ref047","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1464-5491.2012.03640.x","article-title":"Fasting plasma glucose 6\u201312 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis","volume":"29","author":"D Karl","year":"2012","journal-title":"Diabetic medicine: a journal of the British Diabetic Association"},{"issue":"1","key":"pone.0268639.ref048","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3111\/13696998.2013.862538","article-title":"Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study","volume":"17","author":"B Curtis","year":"2014","journal-title":"J Med Econ"},{"issue":"5","key":"pone.0268639.ref049","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2337\/dc11-1307","article-title":"Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort","volume":"35","author":"JD Best","year":"2012","journal-title":"Diabetes care"},{"issue":"39","key":"pone.0268639.ref050","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","article-title":"ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)","volume":"34","author":"L Ryd\u00e9n","year":"2013","journal-title":"European heart journal"},{"key":"pone.0268639.ref051","doi-asserted-by":"crossref","first-page":"108959","DOI":"10.1016\/j.diabres.2021.108959","article-title":"Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence","volume":"178","author":"A Caturano","year":"2021","journal-title":"Diabetes research and clinical practice"},{"key":"pone.0268639.ref052","first-page":"3106056","volume":"2018","author":"FC Sasso","year":"2018","journal-title":"Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes"},{"issue":"2","key":"pone.0268639.ref053","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00003495-199300462-00024","article-title":"The inter-relationship between insulin resistance and hypertension","volume":"46","author":"A Salvetti","year":"1993","journal-title":"Drugs"},{"issue":"4","key":"pone.0268639.ref054","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/jcpt.12690","article-title":"Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis","volume":"43","author":"JY Cui","year":"2018","journal-title":"Journal of clinical pharmacy and therapeutics"},{"issue":"5","key":"pone.0268639.ref055","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1464-5491.2011.03553.x","article-title":"Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes\u2014the CORALL study.","volume":"29","author":"S Simsek","year":"2012","journal-title":"Diabetic medicine: a journal of the British Diabetic Association"},{"issue":"12","key":"pone.0268639.ref056","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jacc.2009.10.053","article-title":"Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients","volume":"55","author":"KK Koh","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"pone.0268639.ref057","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.atherosclerosis.2009.08.031","article-title":"Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes","volume":"209","author":"HL Tam","year":"2010","journal-title":"Atherosclerosis"},{"issue":"639","key":"pone.0268639.ref058","article-title":"Comparison of the Effect of Glycemic Control in Type 2 Diabetes Outpatients Treated With Premixed and Basal Insulin Monotherapy in China.","volume":"9","author":"G Liu","year":"2018","journal-title":"Frontiers in Endocrinology"},{"issue":"1","key":"pone.0268639.ref059","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12933-021-01343-1","article-title":"Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease.","volume":"20","author":"FC Sasso","year":"2021","journal-title":"Cardiovascular Diabetology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0268639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T17:36:24Z","timestamp":1653586584000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0268639"}},"subtitle":[],"editor":[{"given":"Ferdinando Carlo","family":"Sasso","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":59,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0268639","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2022,5,26]]}}}